.svg)
Ladon Therapeutics is a clinical stage biopharmaceutical company
Ladon Therapeutics discovers, develops and commercializes A3SMO® based first-in-class medicines and diagnostics for autoimmune andgenetic diseases with major unmet medical needs.
Ladon Therapeutics brings together breakthrough artificial amino acid-based small molecules chemistry and a state of the art diagnostic laboratory from gene expression profiling to in vivo disease models to characterize, test and evaluate A3SMO® drug candidates.
Gábor is Life Science and Biotech leader with 25+ years diverse experience in emerging and large life science, biotech and pharma.
Gábor is a seasoned executive in building effective, externally focused organizations, raising capital and developing clinical and research product pipelines from small start-up to multinational, integrated clinical stage pharma.
His key areas of expertise include advanced technology platform innovation, asset in-licensing, research and development in pain, oncology, ED, rare diseases, orphan drugs, proctology, CF, infectious diseases, business development.
In his most recent endeavour, Gábor built a pharma company from its birth as a platform technology innovation to becoming a fully-fledged pharmaceutical company with 5 drugs in pivotal clinical programs and an innovative research pipeline of multi-billion dollar market potential.
He holds MSCs in Biology, Chemistry and he has an MBA.
József is an expert of cell biology and pharmacology. He earned his medical degree in 2008 and his Ph.D. in theoretical medicine in 2014 at the Faculty of Medicine, University of Szeged.He studied the role of pancreatic ductal epithelial cells in the pathophysiology of acute pancreatitis. During his Ph.D. studies József became an expert in primary cell isolation and culture technologies, fluorescent microscopy and animal models of inflammatory diseases.
At National Institute of Health (Bethesda, MD, USA) developed advanced cell cultures, molecular biology (molecular cloning) and microscopy techniques (FRET, TIRF, electron microscopy) for the study of molecular physiology of intracellular signalling. He contributed to several publications in leading scientific journals (J Cell Biol. 2013, Nature Communications, 2014).
In 2014 he returned to Hungary and established his laboratory at the University of Szeged. He won several research grants, including the Momentum grant of the Hungarian Academy of Sciences. His laboratory is focused on the epithelial cell signalling and secretion in physiology and pathology and to the development of novel treatments by translating basic findings into patient benefit. His laboratory combines cutting edge cell culture techniques such as 3D organoid cultures with advanced omics and imaging methods. He is the co-inventor of several novel drugs.
István is head of the Institute of Organic Chemistry at Semmelweis University and group leader and PI of Artificial Transporter Research Group at the Research Centre for Natural Sciences of the Hungarian Academy of Sciences.
He is a world renowned expert in the synthesis and characterization of proteomimetic systems including self-organizing peptides and foldamers. He is also a leading expert in continuous-flow synthesis. He earned his PhD in 2011 in foldamer chemistry at the Faculty of Pharmacy, University of Szeged. He was a visiting postgraduate student at Bielefeld University, Germany and University of Joensuu, Finland.
In 2017, he won the prestigious Momentum grant from the Hungarian Academy of Sciences and established his own research group at the Research Centre for Natural Sciences, Budapest. His research focus is on the development of proteomimetic peptide drugs.
His research interest at the Institute of Organic Chemistry at Semmelweis University is focused on break-through green chemical synthesis processes.
He is an author and inventor of numerous high impact peer reviewed publications and patents.
Beáta earned her M.Sc. in Pharmaceutical Chemistry in 2012 from Eötvös Loránd University, Faculty of Sciences.
In 2010 she won the prestigious Nivo prize from the Hungarian Chemical Society.
Before joining Ladon Therapeutics in 2018, she held various management positions including Head of the Laboratory and Head of Development as well as becoming a proud mum of her two beautiful children.
Petra graduated as a biologist in 2007 and she earned her Ph.D. in 2013 in theoretical medicine at the Faculty of Medicine, University of Szeged.
She also hold a position at the MTA-SZTE Momentum Epithelial Cell Signalling and Secretion Research Group in Szeged.
She has developed in depth expertise in sophisticated biomedical techniques as well as cell culture technologies, electrophysiology, different type of microscopy and animal models of inflammatory diseases. Her research focus is on the investigation of the exact mechanism of acute and chronic pancreatitis and corresponding new therapeutic strategies.
Her observations have been published in leading distinguished gastrointestinal journals such as Gastroenterology and Critical Care Medicine.
After Ph.D she won several different fellowships and prestigious awards of different Societies and the Hungarian Academy of Science. She is a member of scientific societies and the editorial boards of scientific journals.
She is a supervisor in the Theoretical Medicine Doctoral School of University of Szeged.
Gábor is Life Science and Biotech leader with 25+ years diverse experience in emerging and large life science, biotech and pharma.
Gábor is a seasoned executive in building effective, externally focused organizations, raising capital and developing clinical and research product pipelines from small start-up to multinational, integrated clinical stage pharma.
His key areas of expertise include advanced technology platform innovation, asset in-licensing, research and development in pain, oncology, ED, rare diseases, orphan drugs, proctology, CF, infectious diseases, business development.
In his most recent endeavour, Gábor built a pharma company from its birth as a platform technology innovation to becoming a fully-fledged pharmaceutical company with 5 drugs in pivotal clinical programs and an innovative research pipeline of multi-billion dollar market potential.
He holds MSCs in Biology, Chemistry and he has an MBA.
József is an expert of cell biology and pharmacology. He earned his medical degree in 2008 and his Ph.D. in theoretical medicine in 2014 at the Faculty of Medicine, University of Szeged.He studied the role of pancreatic ductal epithelial cells in the pathophysiology of acute pancreatitis. During his Ph.D. studies József became an expert in primary cell isolation and culture technologies, fluorescent microscopy and animal models of inflammatory diseases.
At National Institute of Health (Bethesda, MD, USA) developed advanced cell cultures, molecular biology (molecular cloning) and microscopy techniques (FRET, TIRF, electron microscopy) for the study of molecular physiology of intracellular signalling. He contributed to several publications in leading scientific journals (J Cell Biol. 2013, Nature Communications, 2014).
In 2014 he returned to Hungary and established his laboratory at the University of Szeged. He won several research grants, including the Momentum grant of the Hungarian Academy of Sciences. His laboratory is focused on the epithelial cell signalling and secretion in physiology and pathology and to the development of novel treatments by translating basic findings into patient benefit. His laboratory combines cutting edge cell culture techniques such as 3D organoid cultures with advanced omics and imaging methods. He is the co-inventor of several novel drugs.
István is head of the Institute of Organic Chemistry at Semmelweis University and group leader and PI of Artificial Transporter Research Group at the Research Centre for Natural Sciences of the Hungarian Academy of Sciences.
He is a world renowned expert in the synthesis and characterization of proteomimetic systems including self-organizing peptides and foldamers. He is also a leading expert in continuous-flow synthesis. He earned his PhD in 2011 in foldamer chemistry at the Faculty of Pharmacy, University of Szeged. He was a visiting postgraduate student at Bielefeld University, Germany and University of Joensuu, Finland.
In 2017, he won the prestigious Momentum grant from the Hungarian Academy of Sciences and established his own research group at the Research Centre for Natural Sciences, Budapest. His research focus is on the development of proteomimetic peptide drugs.
His research interest at the Institute of Organic Chemistry at Semmelweis University is focused on break-through green chemical synthesis processes.
He is an author and inventor of numerous high impact peer reviewed publications and patents.
Beáta earned her M.Sc. in Pharmaceutical Chemistry in 2012 from Eötvös Loránd University, Faculty of Sciences.
In 2010 she won the prestigious Nivo prize from the Hungarian Chemical Society.
Before joining Ladon Therapeutics in 2018, she held various management positions including Head of the Laboratory and Head of Development as well as becoming a proud mum of her two beautiful children.
Petra graduated as a biologist in 2007 and she earned her Ph.D. in 2013 in theoretical medicine at the Faculty of Medicine, University of Szeged.
She also hold a position at the MTA-SZTE Momentum Epithelial Cell Signalling and Secretion Research Group in Szeged.
She has developed in depth expertise in sophisticated biomedical techniques as well as cell culture technologies, electrophysiology, different type of microscopy and animal models of inflammatory diseases. Her research focus is on the investigation of the exact mechanism of acute and chronic pancreatitis and corresponding new therapeutic strategies.
Her observations have been published in leading distinguished gastrointestinal journals such as Gastroenterology and Critical Care Medicine.
After Ph.D she won several different fellowships and prestigious awards of different Societies and the Hungarian Academy of Science. She is a member of scientific societies and the editorial boards of scientific journals.
She is a supervisor in the Theoretical Medicine Doctoral School of University of Szeged.
Petra graduated as a biologist in 2007 and she earned her Ph.D. in 2013 in theoretical medicine at the Faculty of Medicine, University of Szeged.
She also hold a position at the MTA-SZTE Momentum Epithelial Cell Signalling and Secretion Research Group in Szeged.
She has developed in depth expertise in sophisticated biomedical techniques as well as cell culture technologies, electrophysiology, different type of microscopy and animal models of inflammatory diseases. Her research focus is on the investigation of the exact mechanism of acute and chronic pancreatitis and corresponding new therapeutic strategies.
Her observations have been published in leading distinguished gastrointestinal journals such as Gastroenterology and Critical Care Medicine.
After Ph.D she won several different fellowships and prestigious awards of different Societies and the Hungarian Academy of Science. She is a member of scientific societies and the editorial boards of scientific journals.
She is a supervisor in the Theoretical Medicine Doctoral School of University of Szeged.
Beáta earned her M.Sc. in Pharmaceutical Chemistry in 2012 from Eötvös Loránd University, Faculty of Sciences.In 2010 she won the prestigious Nivo prize from the Hungarian Chemical Society.Before joining Ladon Therapeutics in 2018, she held various management positions including Head of the Laboratory and Head of Development as well as becoming a proud mum of her two beautiful children.LiIg
József is an expert of cell biology and pharmacology. He earned his medical degree in 2008 and his Ph.D. in theoretical medicine in 2014 at the Faculty of Medicine, University of Szeged.
He studied the role of pancreatic ductal epithelial cells in the pathophysiology of acute pancreatitis. During his Ph.D. studies József became an expert in primary cell isolation and culture technologies, fluorescent microscopy and animal models of inflammatory diseases.
At National Institute of Health (Bethesda, MD, USA) developed advanced cell cultures, molecular biology (molecular cloning) and microscopy techniques (FRET, TIRF, electron microscopy) for the study of molecular physiology of intracellular signalling. He contributed to several publications in leading scientific journals (J Cell Biol. 2013, Nature Communications, 2014).
In 2014 he returned to Hungary and established his laboratory at the University of Szeged. He won several research grants, including the Momentum grant of the Hungarian Academy of Sciences. His laboratory is focused on the epithelial cell signalling and secretion in physiology and pathology and to the development of novel treatments by translating basic findings into patient benefit. His laboratory combines cutting edge cell culture techniques such as 3D organoid cultures with advanced omics and imaging methods. He is the co-inventor of several novel drugs.
István is head of the Institute of Organic Chemistry at Semmelweis University and group leader and PI of Artificial Transporter Research Group at the Research Centre for Natural Sciences of the Hungarian Academy of Sciences.
He is a world renowned expert in the synthesis and characterization of proteomimetic systems including self-organizing peptides and foldamers. He is also a leading expert in continuous-flow synthesis. He earned his PhD in 2011 in foldamer chemistry at the Faculty of Pharmacy, University of Szeged. He was a visiting postgraduate student at Bielefeld University, Germany and University of Joensuu, Finland.
In 2017, he won the prestigious Momentum grant from the Hungarian Academy of Sciences and established his own research group at the Research Centre for Natural Sciences, Budapest. His research focus is on the development of proteomimetic peptide drugs.
His research interest at the Institute of Organic Chemistry at Semmelweis University is focused on break-through green chemical synthesis processes.
He is an author and inventor of numerous high impact peer reviewed publications and patents.
Gábor is Life Science and Biotech leader with 25+ years diverse experience in emerging and large life science, biotech and pharma.
Gábor is a seasoned executive in building effective, externally focused organizations, raising capital and developing clinical and research product pipelines from small start-up to multinational, integrated clinical stage pharma.
His key areas of expertise include advanced technology platform innovation, asset in-licensing, research and development in pain, oncology, ED, rare diseases, orphan drugs, proctology, CF, infectious diseases, business development.
In his most recent endeavour, Gábor built a pharma company from its birth as a platform technology innovation to becoming a fully-fledged pharmaceutical company with 5 drugs in pivotal clinical programs and an innovative research pipeline of multi-billion dollar market potential.
He holds MSCs in Biology, Chemistry and he has an MBA.
.png)
.webp)
Our vision is to be a pioneering bio-pharmaceutical company that cures debilitating diseases through breakthrough scientific innovations.
.svg)
Our mission is to discover, develop and commercialise A3SMO® based medicines and diagnostics for autoimmune and genetic diseases with the greatest unmet medical needs where current therapies are inadequate.
Discover and Develop a new generation of A3SMO® based therapies
Embrace and Encourage diversity of cultures, ideas and approaches
Always try to be your best, always think quality over quantity
The Team is always greater than the sum of the individuals
Our core values represent who we are, what we strive to achieve and how we want to get there.
.png)
.svg)
.svg)
.svg)
